Cure My Disease

Don't miss your cure!

 Log in / Sign up

Teplizumab's Real-World impact on type 1 diabetes under scrutiny

NCT ID NCT07360080

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 1,000 people with Stage 2 Type 1 Diabetes who have received teplizumab in routine care. Researchers will track how long it takes for the disease to progress to Stage 3 and assess quality of life. The goal is to see if teplizumab delays the need for insulin therapy in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
teplizumab
What this could lead to
If successful, this study could confirm that teplizumab effectively delays the onset of full-blown Type 1 Diabetes in real-world settings, improving long-term disease management.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. Teplizumab may not work for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number: 3760001

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Investigational Site Number: 8400003

    RECRUITING

    Atlanta, Georgia, 30318-2538, United States

  • Investigational Site Number: 8400005

    RECRUITING

    Sandy City, Utah, 84093, United States

  • Investigative Site Number: 3760002

    RECRUITING

    Ramat Gan, 52621, Israel

  • Investigative Site Number: 3760003

    RECRUITING

    Petah Tikva, 4920235, Israel

  • Investigative Site Number: 7840001

    RECRUITING

    Abu Dhabi, United Arab Emirates

  • Investigative Site Number: 8400002

    RECRUITING

    Syosset, New York, 11791, United States

  • Investigative Site Number: 8400004

    RECRUITING

    Atlanta, Georgia, 30329-3102, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.